CompletedPhase 2NCT03023124
Study With Trabectedin Versus Adriamycin Plus Dacarbazine, in Patients With Advanced Solitary Fibrous Tumor
Studying Solitary fibrous tumor
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Italian Sarcoma Group
- Principal Investigator
- Silvia Stacchiotti, MDItalian Sarcoma Group
- Intervention
- Trabectedin(drug)
- Enrollment
- 23 target
- Eligibility
- 18 years · All sexes
- Timeline
- 2018 – 2024
Study locations (6)
- Nuovo Ospedale di Prato, Prato, Firenze, Italy
- Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, MI, Italy
- Policlinico Universitario Campus Biomedico, Roma, RM, Italy
- IRCCS Istituto ortopedico Rizzoli, Bologna, Italy
- Fondazione Del Piemonte Per L'Oncologia Ircc Di Candiolo -, Candiolo, Italy
- Ospedale Giaccone, Palermo, Italy
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT03023124 on ClinicalTrials.gov